Epsilon Healthcare Limited (ASX: EPN)
Health Care · Pharmaceuticals · AU
AU$0.03
+31.82% today · -17.1% 1Y
Epsilon Healthcare Limited (ASX: EPN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.09M and employs 14 people.
Over the last twelve months the share price has lost 17.1%, trading between 0.02 and 0.04.
Tweenvest scores Epsilon Healthcare Limited across four factors: quality 33/100, value 39/100, growth 100/100. Its strongest factor is growth.
EPN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.09M
- Revenue (TTM)
- $6.27M
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.77
- 52-week high
- AU$0.04
- 52-week low
- AU$0.02
- Avg volume (3M)
- —
- Shares outstanding
- 389.10M
- Employees
- 14
- Next earnings
- —
About Epsilon Healthcare Limited
Epsilon Healthcare Limited operates as an Australian-based healthcare and pharmaceutical firm, with significant operations also extending into Canada. Established in 2016 and headquartered in Sydney, the company specializes in several areas: manufacturing and distributing a range of hydroponic supplies, including equipment, materials, and vital nutrients; developing and providing medicinal cannabis products; and offering comprehensive, ready-to-implement solutions for cannabis cultivation. The company officially rebranded from THC Global Group Limited to Epsilon Healthcare Limited in February 2021.
- ISIN
- AU0000137598
- Founded
- 2016
- Listed since
- May 4, 2017
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.50 | -0.01% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.20 | +0.02% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $155.85 | -0.38% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.